



# **NEWS RELEASE**

**FOR IMMEDIATE RELEASE**

**CONTACTS:**

Media:  
Sheryl Seapy  
Pure Communications  
949-608-0841

**XDx to Present at the 2008 In Vitro Diagnostic  
Regulatory and Reimbursement Conference**

**BRISBANE, California, November 18, 2008** – XDx, a molecular diagnostic company, today announced that Pierre Cassigneul, president and chief executive officer, is scheduled to present at the 2008 In Vitro Diagnostic Regulatory and Reimbursement Conference on November 18, 2008 at 9 a.m. (ET) at the Hyatt Regency Baltimore.

Cassigneul will present a keynote lecture, entitled “XDx’s Innovative Reimbursement Strategy,” that will highlight AlloMap® Molecular Expression Testing. AlloMap is a noninvasive, multi-gene molecular diagnostics blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing, in conjunction with standard clinical assessment.

In August, AlloMap received market clearance from the U.S. Food and Drug Administration (FDA), making XDx the first U.S. molecular diagnostics company to obtain FDA clearance of an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for use in transplant management.

“AlloMap clearance provides physicians with a non-invasive test to assist in the management of potential organ rejection of heart transplant patients,” said Cassigneul. “We look forward to participating in the In Vitro Diagnostic Regulatory and Reimbursement Conference, and sharing our best practices with other members of the healthcare community.”

**About XDx**

Based in Brisbane, California, XDx is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed a proprietary new method for noninvasively monitoring immune system activity by measuring gene expression in a patient’s peripheral blood. This work is the

basis for AlloMap Molecular Expression Testing, which provides transplant physicians with a new tool to aid in the identification of the probability of acute cellular rejection for postcardiac transplant patient management.

Some of the AlloMap Molecular Expression Technology developed and implemented by XDx in heart transplant patient management may be applicable to other diseases that involve transplant rejection and the immune system. XDx's noninvasive technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.

**About the In Vitro Diagnostic Regulatory & Reimbursement Conference**

The In Vitro Diagnostic Regulatory & Reimbursement Conference is a comprehensive and multidisciplinary forum where leaders in the global health community will discuss health economics and its role in the value of diagnostics. This forum will focus on regulatory, market access and reimbursement strategies for innovative products. The In Vitro Diagnostic Regulatory & Reimbursement Conference will be held on November 17-18, 2008 at the Hyatt Regency Baltimore. For more information, visit [www.q1productions.com](http://www.q1productions.com).

###